A Phase 4 interventional study of chloroprocaine HCL 3% and Subconjunctival Lidocaine in No Condition, sponsored by Retina Research Institute, LLC. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Retina Research Institute, LLC · Phase 4, Interventional, and Treatment
This will be a prospective, randomized, controlled non-inferiority trial comparing the efficacy of Iheezo versus subconjunctival 2% lidocaine in reducing intravitreal injection pain scores up to 24 hours after injection.
The purpose of this study is to assess and compare patient pain and symptom levels up to 24 hours post-intravitreal injection when using Iheezo (Chloroprocaine HCl ophthalmic gel 3%) versus subconjunctival Lidocaine (2%) for pre-procedure anesthesia. Both medications are approved to be used for pre-procedure anesthesia. Approximately 80 subjects will participate in this study.
Retina Research Institute, LLC is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: chloroprocaine HCL 3%
Drug: Subconjunctival Lidocaine
Topical anesthetic for intravitreal injection
Procedural anesthetic for intravitreal injection
Pain Scores
Patient-reported ocular pain 4 hours after intravitreal injection using Visual Analog Pain Score Surveys.
Time frame: 4 hourse
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chloroprocaine
Retina Research Institute, LLC